Fritzsche, Florian R. and Jung, Monika and Toelle, Angelika and Wild, Peter and Hartmann, Arndt and Wassermann, Kirsten and Rabien, Anja and Lein, Michael and Dietel, Manfred and Pilarsky, Christian and Calvano, Daniela and Gruetzmann, Robert and Jung, Klaus and Kristiansen, Glen (2008) ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. EUROPEAN UROLOGY, 54 (5). pp. 1097-1108. ISSN 0302-2838,
Full text not available from this repository. (Request a copy)Abstract
Objectives: A disintegrin and metalloprotease (ADAM) 9 has been implicated in tumour progression of prostate cancer. We evaluated the expression of ADAM9 on protein and messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following prostatectomy and correlated the findings with clinicopathological parameters including prostate-specific antigen (PSA) relapse times. Methods: We immunostained 198 clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analysed via quantitative reverse transcriptase-polymerase chain reaction. Results: ADAM9 was significantly upregulated in prostate cancer compared with normal tissue on mRNA and protein level. ADAM9 protein expression was significantly associated with shortened PSA relapse-free survival in univariate and multivariate analyses, particularly in patients who had received prior androgen ablation. Conclusions: ADAM9 is overexpressed in prostate cancer cases and is an independent prognostic marker of PSA relapse-free survival following radical prostatectomy. Further studies are needed to verify its role as a predictive marker of response to androgen ablation. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HUMAN BREAST-CANCER; GENE-EXPRESSION; GROWTH-FACTOR; CELL-LINES; METALLOPROTEASE-DISINTEGRIN; DUCTAL ADENOCARCINOMA; PANCREATIC-CANCER; GASTRIC-CANCER; SECRETED FORM; ADHESION; ADAM9; Immunohistochemistry; qRT-PCR; Prognostic marker; Prostate cancer |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Oct 2020 09:41 |
| Last Modified: | 19 Oct 2020 09:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/30094 |
Actions (login required)
 |
View Item |
